Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Prudential Financial Inc.

Prudential Financial Inc. boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 25.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 559,765 shares of the company’s stock after purchasing an additional 112,352 shares during the period. Prudential Financial Inc.’s holdings in Teva Pharmaceutical Industries were worth $12,337,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock valued at $859,935,000 after buying an additional 4,418,961 shares during the period. Lingotto Investment Management LLP lifted its holdings in Teva Pharmaceutical Industries by 2.6% in the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock valued at $599,320,000 after acquiring an additional 688,862 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in Teva Pharmaceutical Industries by 2.2% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock valued at $573,822,000 after acquiring an additional 569,412 shares during the last quarter. State Street Corp boosted its position in shares of Teva Pharmaceutical Industries by 10.0% during the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company’s stock valued at $351,402,000 after purchasing an additional 1,778,268 shares in the last quarter. Finally, AustralianSuper Pty Ltd grew its stake in shares of Teva Pharmaceutical Industries by 16.8% in the 4th quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company’s stock worth $203,268,000 after purchasing an additional 1,329,319 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Bank of America dropped their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Finally, Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Trading Down 2.8 %

Shares of NYSE TEVA opened at $15.06 on Friday. The firm has a market capitalization of $17.07 billion, a PE ratio of -10.38, a PEG ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The business has a 50-day moving average price of $17.21 and a two-hundred day moving average price of $18.12.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.